View this email in your browser ([link removed])
[link removed]
[link removed]

Your source for the latest news in drug policy. Visit our website ([link removed]) for more news.

A recent report ([link removed]) from the Office of the Inspector General, within the federal Department of Health and Human Services, found that “in 2023, about 1.2 million Medicare enrollees had a diagnosis of opioid use disorder. Yet just 229,993 of these enrollees—18.7 percent—received medication for opioid use disorder.”

This percentage “represents several years of minimal growth.” The percentage of Medicare enrollees with opioid use disorder that received medications increased from 15.9% in 2020 to 17.7% in 2021, 18.4% in 2022, and 18.7% in 2023. Among those who received treatment, the majority received buprenorphine, while others received methadone or naltrexone.

Despite the removal of the “X Waiver,” which had required healthcare providers to obtain a waiver to prescribe buprenorphine, the report noted that the low percentage “may indicate that enrollees are facing ongoing challenges accessing treatment.”

In particular, “Medicare enrollees in Florida, Texas, and Nevada continue to be the least likely to receive medication for their opioid use disorder,” where less than 10% received medications for opioid use disorder. The five states with the highest percentages were Vermont (60%), Maine (51%), Massachusetts (50%), Rhode Island (50%), and New Hampshire (43%).

The report concluded that “these findings show a continued need for CMS to work to ensure access to both medications for opioid use disorder and opioid overdose-reversal drugs.”

Received this email from a friend? Sign up here! ([link removed])
[link removed]

[link removed]
[link removed]
[link removed]
[link removed]
[link removed]

Foundation for Drug Policy Solutions (FDPS) ([link removed]) is an organization that envisions a world in which children and families thrive, substance use is prevented, and there is rapid access to quality treatment and meaningful pathways to recovery for individuals with substance use disorders. Our mission is to scale up drug policy solutions by educating decision-makers and the public about ways to harness science to prevent drug use, treat addiction, and forge pathways to recovery.

Copyright (C) 2025 The Drug Report. All rights reserved.
You are receiving this email because you opted in at our website, gooddrugpolicy.org or through the Smart Approaches to Marijuana website, learnaboutsam.org.
Our mailing address is:
The Drug Report 107 S West St Ste. 757 Alexandria, VA 22314 USA

Want to change how you receive these emails?
You can update your preferences ([link removed][UNIQID]&c=65f7be511c) or unsubscribe ([link removed][UNIQID]&c=65f7be511c)

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Smart Approaches to Marijuana (SAM) . 107 S West St. Ste. 757 . Alexandria, VA 22314 . USA